Cited by 318Glioma Diagnosis and TreatmentAdvanced MRI Techniques and ApplicationsMetabolomics and Mass Spectrometry Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Open access

Pope, Whitney B., Prins, Robert M., Albert Thomas, M., Nagarajan, Rajakumar, Yen, Katharine E., Bittinger, Mark A., Salamon, Noriko, Chou, Arthur P., Yong, William H., Soto, Horacio, Wilson, Neil, Driggers, Edward, Jang, Hyun G., Su, Shinsan M., Schenkein, David P., Lai, Albert, Cloughesy, Timothy F., Kornblum, Harley I., Wu, Hong, Fantin, Valeria R., Liau, Linda M.·2012·Journal of Neuro-Oncology

DOI 10.1007/s11060-011-0737-8PMC PMC3650613

Open this paper in CoChat — free account

Abstract

Mutations of the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are commonly found in primary brain cancers. We previously reported that a novel enzymatic activity of these mutations results in the production of the putative oncometabolite, R(-)-2-hydroxyglutarate (2-HG). Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors. Patients with intrinsic glial brain tumors (n = 27) underwent structural and spectroscopic magnetic resonance imaging prior to surgery. 2-HG levels from MRS data were quantified using LC-Model software, based upon a simulated spectrum obtained from a GAMMA library added to the existing prior knowledge database. The resected tumors were then analyzed for IDH1 mutational status by genomic DNA sequencing, Ki-67 proliferation index by immunohistochemistry, and concentrations of 2-HG and other metabolites by liquid chromatography-mass spectrometry (LC-MS). MRS detected elevated 2-HG levels in gliomas with IDH1 mutations compared to those with wild-type IDH1 (P = 0.003). The 2-HG levels measured in vivo with MRS were significantly correlated with those measured ex vivo from the corresponding tumor samples using LC-MS (r (2) = 0.56; P = 0.0001). Compared with wild-type tumors, those with IDH1 mutations had elevated choline (P = 0.01) and decreased glutathione (P = 0.03) on MRS. Among the IDH1 mutated gliomas, quantitative 2-HG values were correlated with the Ki-67 proliferation index of the tumors (r ( 2 ) = 0.59; P = 0.026). In conclusion, water-suppressed proton ((1)H) MRS provides a non-invasive measure of 2-HG in gliomas, and may serve as a potential biomarker for patients with IDH1 mutant brain tumors. In addition to 2-HG, alterations in several other metabolites measured by MRS correlate with IDH1 mutation status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s11060-011-0737-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
Provencher, S. W. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300604 · Cited by 3,659
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer
WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Spatial Localization in NMR Spectroscopy in Vivo
Bottomley, P. A. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb32915.x · Cited by 1,382
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163

Show all 32 references

Research works printed but not linked: 1

Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(21):2248 author reply 9 · DOI

Sorted by citations

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Metabolic pathways promoting cancer cell survival and growth
Boroughs, L. K., & DeBerardinis, R. J. (2015) · Nature Cell Biology · doi:10.1038/ncb3124 · Cited by 1,499
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
Glutathione levels in human tumors
Gamcsik, M. P., Kasibhatla, M. S., Teeter, S. D., & Colvin, O. M. (2012) · Biomarkers · doi:10.3109/1354750x.2012.715672 · Cited by 608
Emerging insights into the molecular and cellular basis of glioblastomaPreprint
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 573
IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 477
Oncometabolites: linking altered metabolism with cancer
Yang, M. H., Soga, T., & Pollard, P. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67228 · Cited by 441
Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging
Chang, K., Bai, H. X., Zhou, H., Su, C., Bi, W. L., Agbodza, E., Kavouridis, V. K., Senders, J. T., Boaro, A., Beers, A. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2236 · Cited by 392
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
McBrayer, S. K., Mayers, J. R., DiNatale, G. J., Shi, D. D., Khanal, J., Chakraborty, A. A., Sarosiek, K. A., Briggs, K. J., Robbins, A. K., Sewastianik, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.038 · Cited by 368
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas
Zhang, B., Chang, K., Ramkissoon, S. H., Tanguturi, S. K., Bi, W. L., Reardon, D. A., Ligon, K. L., Alexander, B. M., Wen, P. Y., & Huang, R. Y. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now121 · Cited by 262
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery
Santagata, S., Eberlin, L. S., Norton, I. H., Calligaris, D., Feldman, D. R., Ide, J. L., Liu, X., Wiley, J. S., Vestal, M. L., Ramkissoon, S. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404724111 · Cited by 264
A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds
Kalyanaraman, B., Cheng, G., Hardy, M., Ouari, O., López, M., Joseph, J., Zielonka, J., & Dwinell, M. B. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.020 · Cited by 239
The role of neuropathology in the management of patients with diffuse low grade glioma
Cahill, D. P., Sloan, A. E., Nahed, B. V., Aldape, K., Louis, D. N., Ryken, T. C., Kalkanis, S. N., & Olson, J. J. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1909-8 · Cited by 230
Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma
Yu, J., Shi, Z., Lian, Y., Li, Z., Liu, T., Gao, Y., Wang, Y., Chen, L., & Mao, Y. Q. (2016) · European Radiology · doi:10.1007/s00330-016-4653-3 · Cited by 216
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods
Mountz, J. M., Ahmed, R., Oborski, M. J., Lieberman, F. S., & Hwang, M. (2014) · Cancer Management and Research · doi:10.2147/cmar.s54726 · Cited by 214
Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH -Mutant Glioma
Choi, C., Raisanen, J. M., Ganji, S. K., Zhang, S., McNeil, S. S., An, Z., Madan, A., Hatanpaa, K. J., Vemireddy, V., Sheppard, C. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1222 · Cited by 201
Combining molecular and imaging metrics in cancer: radiogenomics
Gullo, R. L., Naranjo, I. D., Morris, E. A., & Pinker, K. (2020) · Insights into Imaging · doi:10.1186/s13244-019-0795-6 · Cited by 183
Imaging Correlates of Adult Glioma Genotypes
Smits, M., & van den Bent, M. J. (2017) · Radiology · doi:10.1148/radiol.2017151930 · Cited by 180
2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know
Johnson, D. R., Guerin, J. B., Giannini, C., Morris, J. M., Eckel, L. J., & Kaufmann, T. J. (2017) · Radiographics · doi:10.1148/rg.2017170037 · Cited by 180
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 178
Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI
Jiang, S., Zou, T., Eberhart, C. G., Villalobos, M. A. V., Heo, H., Zhang, Y., Wang, Y., Wang, X., Yu, H., Du, Y., et al. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26820 · Cited by 172
Emerging Therapies for Glioblastoma
Thomas, A. A., Brennan, C., DeAngelis, L. M., & Omuro, A. M. P. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1701 · Cited by 173
Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T
Paech, D., Windschuh, J., Oberhollenzer, J., Dreher, C., Sahm, F., Meissner, J., Goerke, S., Schuenke, P., Zaiß, M., Regnery, S., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy073 · Cited by 166
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
Andronesi, O. C., Loebel, F., Bogner, W., Marjańska, M., Heiden, M. G. V., Iafrate, A. J., Dietrich, J., Batchelor, T. T., Gerstner, E. R., Kaelin, W. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0656 · Cited by 153
Non-invasive in vivo assessment of IDH1 mutational status in glioma
Chaumeil, M. M., Larson, P. E. Z., Yoshihara, H. A. I., Danforth, O. M., Vigneron, D. B., Nelson, S. J., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2013) · Nature Communications · doi:10.1038/ncomms3429 · Cited by 142
Retracted: A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas
Yogananda, C. G. B., Shah, B., Vejdani‐Jahromi, M., Nalawade, S. S., Murugesan, G. K., Yu, F. F., Pinho, M. C., Wagner, B., Mickey, B., Patel, T., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz199 · Cited by 138
Retracted
Radiogenomic Analysis of Oncological Data: A Technical Survey
Incoronato, M., Aiello, M., Infante, T., Cavaliere, C., Grimaldi, A., Mirabelli, P., Monti, S., & Salvatore, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040805 · Cited by 138
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
Zhang, C., Moore, L. M., Li, X., Yung, W. K. A., & Zhang, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not087 · Cited by 136
Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas
Zhou, H., Chang, K., Bai, H. X., Xiao, B., Su, C., Bi, W. L., Zhang, P. J., Senders, J. T., Vallières, M., Kavouridis, V. K., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03096-0 · Cited by 130
2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data
Suh, C. H., Kim, H. S., Jung, S. C., Choi, C. G., & Kim, S. J. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy113 · Cited by 128
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 128
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
Izquierdo-Garcia, J. L., Viswanath, P., Eriksson, P., Cai, L., Radoul, M., Chaumeil, M. M., Blough, M., Luchman, H. A., Weiss, S., Cairncross, J. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0840 · Cited by 123
Alterations of metabolic genes and metabolites in cancer
Oermann, E. K., Wu, J., Guan, K., & Xiong, Y. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.013 · Cited by 125
Imaging genomics in cancer research: limitations and promises
Bai, H. X., Lee, A. M., Yang, L., Zhang, P. J., Davatzikos, C. A., Maris, J. M., & Diskin, S. J. (2016) · British Journal of Radiology · doi:10.1259/bjr.20151030 · Cited by 114
Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges
Zhang, J., Liu, H., Tong, H., Wang, S., Yang, Y., Liu, G., & Zhang, W. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/7064120 · Cited by 111
Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups
Juratli, T. A., Tummala, S. S., Riedl, A., Daubner, D., Hennig, S., Penson, T., Zolal, A., Thiede, C., Schackert, G., Krex, D., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03034-6 · Cited by 112
Detection of IDH1 mutation in the plasma of patients with glioma
Boisselier, B., Pérez‐Larraya, J. G., Rossetto, M., Labussière, M., Ciccarino, P., Marie, Y., Delattre, J., & Sanson, M. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e9b0a · Cited by 110
In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors
Salamanca-Cardona, L., Shah, H., Poot, A. J., Correa, F. M., Di Gialleonardo, V., Lui, H., Miloushev, V. Z., Granlund, K. L., Tee, S. S., Cross, J. R., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.001 · Cited by 106
Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review
Kazerooni, A. F., Bakas, S., Rad, H. S., & Davatzikos, C. A. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26907 · Cited by 104
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging
Lee, S., Choi, S. H., Ryoo, I., Yoon, T. J., Kim, T. M., Lee, S., Park, C., Kim, J., Sohn, C., Park, S., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1614-z · Cited by 104
IDH inhibition in gliomas: from preclinical models to clinical trials
Rudà, R., Horbinski, C., van den Bent, M. J., Preusser, M., & Soffietti, R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00967-7 · Cited by 105
GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients
Nakamizo, S., Sasayama, T., Shinohara, M., Irino, Y., Nishiumi, S., Nishihara, M., Tanaka, H., Tanaka, K., Mizukawa, K., Itoh, T., et al. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1090-x · Cited by 101
Conventional and advanced magnetic resonance imaging in patients with high-grade glioma
Pope, W. B., & Brandal, G. (2018) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.18.03086-8 · Cited by 106
Self-citation
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
Liu, A., Hou, C., Chen, H., Zong, X., & Zong, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00016 · Cited by 105
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting
Tietze, A., Choi, C., Mickey, B., Maher, E. A., Ulhøi, B. P., Sangill, R., Lassen–Ramshad, Y., Lukacova, S., Østergaard, L., & von Öettingen, G. (2017) · Journal of neurosurgery · doi:10.3171/2016.10.jns161793 · Cited by 90
Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma
Chaumeil, M. M., Larson, P. E. Z., Woods, S. M., Cai, L., Eriksson, P., Robinson, A. E., Lupo, J., Vigneron, D. B., Nelson, S. J., Pieper, R. O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0680 · Cited by 87
Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy
Branzoli, F., Stefano, A. L. D., Capelle, L., Ottolenghi, C., Valabrègue, R., Deelchand, D. K., Bielle, F., Villa, C., Baussart, B., Lehéricy, S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox214 · Cited by 88
Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
Garrett, M. C., Sperry, J., Braas, D., Yan, W., Le, T. M., Mottahedeh, J., Ludwig, K., Eskin, A., Qin, Y., Levy, R., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0177-4 · Cited by 86
Self-citation
Genetically-defined metabolic reprogramming in cancer
Mullen, A. R., & DeBerardinis, R. J. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.06.009 · Cited by 90
IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma
Esmaeili, M., Hamans, B. C., Navis, A. C., van Horssen, R., Bathen, T. F., Gribbestad, I. S., Leenders, W. P. J., & Heerschap, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0008 · Cited by 86
MRI radiomics analysis of molecular alterations in low-grade gliomas
Shofty, B., Artzi, M., Bashat, D. B., Liberman, G., Haim, O., Kashanian, A., Bokstein, F., Blumenthal, D. T., Ram, Z., & Shahar, T. (2017) · International Journal of Computer Assisted Radiology and Surgery · doi:10.1007/s11548-017-1691-5 · Cited by 86
A comparative study of short‐ and long‐TE 1H MRS at 3 T for in vivo detection of 2‐hydroxyglutarate in brain tumors
Choi, C., Ganji, S., Hulsey, K., Madan, A., Kovács, Z. Z., Dimitrov, I. E., Zhang, S., Pichumani, K., Mendelsohn, D. B., Mickey, B., et al. (2013) · NMR in Biomedicine · doi:10.1002/nbm.2943 · Cited by 83
Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma
Kalinina, J., Carroll, A., Wang, L., Yu, Q., Mancheno, D. E., Wu, S., Liu, F., Ahn, J. Y., He, M., Mao, H. Z., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0888-x · Cited by 84
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma
Chen, L., Voronovich, Z. A., Clark, K., Hands, I., Mannas, J., Walsh, M., Nikiforova, M. N., Durbin, E. B., Weiss, H. L., & Horbinski, C. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou097 · Cited by 82
Metabolic Reprogramming in Mutant IDH1 Glioma Cells
Izquierdo-García, J. L., Viswanath, P., Eriksson, P., Chaumeil, M. M., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118781 · Cited by 90
Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma
Jalbert, L. E., Elkhaled, A., Phillips, J. J., Neill, E., Williams, A. A., Crane, J. C., Olson, M. P., Molinaro, A. M., Berger, M. S., Kurhanewicz, J. V., et al. (2017) · Scientific Reports · doi:10.1038/srep44792 · Cited by 80
7 Tesla and Beyond
Platt, T., Ladd, M. E., & Paech, D. (2021) · Investigative Radiology · doi:10.1097/rli.0000000000000820 · Cited by 81
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy forIDH1mutant glioma
Nagashima, H., Tanaka, K., Sasayama, T., Irino, Y., Sato, N., Takeuchi, Y., Kyotani, K., Mukasa, A., Mizukawa, K., Sakata, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now090 · Cited by 76
The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas
Patel, T., Bander, E. D., Venn, R. A., Powell, T. M., Cederquist, G., Schaefer, P. M., Puchi, L. A., Akhmerov, A., Ogilvie, S. Q., Reiner, A. S., et al. (2017) · Neurosurgery · doi:10.1093/neuros/nyx265 · Cited by 67
Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring
Chaumeil, M. M., Radoul, M., Najac, C., Eriksson, P., Viswanath, P., Blough, M. D., Chesnelong, C., Luchman, H. A., Cairncross, J. G., & Ronen, S. M. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.06.018 · Cited by 67
Non-Invasive Tumor Genotyping Using Radiogenomic Biomarkers, a Systematic Review and Oncology-Wide Pathway Analysis
Jansen, R. W., van Amstel, P., Martens, R. M., Kooi, I. E., Wesseling, P., de Langen, A. J., Menke-Van der Houven van Oordt, C. W., Jansen, B. H. E., Moll, A. C., Dorsman, J. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24893 · Cited by 63
Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness
Tiwari, V., Daoud, E. V., Hatanpaa, K. J., Gao, A., Zhang, S., An, Z., Ganji, S., Raisanen, J. M., Lewis, C. M., Askari, P., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa034 · Cited by 65
Diseases of the Brain, Head and Neck, Spine 2020–2023
Hodler, J., Huch, R., & von Schulthess, G. K. (2020) · IDKD Springer series · doi:10.1007/978-3-030-38490-6 · Cited by 65
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy
Natsumeda, M., Igarashi, H., Nomura, T., Ogura, R., Tsukamoto, Y., Kobayashi, T., Aoki, H., Okamoto, K., Kakita, A., Takahashi, H., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0158-y · Cited by 64
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
Leather, T., Jenkinson, M. D., Das, K., & Poptani, H. (2017) · Metabolites · doi:10.3390/metabo7020029 · Cited by 65
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
Batsios, G., Viswanath, P., Subramani, E., Najac, C., Gillespie, A. M., Santos, R. D., Molloy, A. R., Pieper, R. O., & Ronen, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47021-x · Cited by 63
Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases
Tan, W., Huang, W., Yin, B., Xiong, J., Wu, J., & Geng, D. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3803 · Cited by 63
Noninvasively detectingIsocitrate dehydrogenase 1gene status in astrocytoma by dynamic susceptibility contrast MRI
Tan, W., Xiong, J., Huang, W., Wu, J., Zhan, S., & Geng, D. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25358 · Cited by 63
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Liu, Y., Lang, F., Chou, F.-J., Zaghloul, K. A., & Yang, C. (2020) · Biomedicines · doi:10.3390/biomedicines8090294 · Cited by 62
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
Advanced MR Techniques for Preoperative Glioma Characterization: Part 2
Hangel, G. J., Schmitz‐Abecassis, B., Sollmann, N., Pinto, J., Arzanforoosh, F., Barkhof, F., Booth, T. C., Calvo‐Imirizaldu, M., Cassia, G. D. S. E., Chmelík, M., et al. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28663 · Cited by 60
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
IDH1/2 mutation detection in gliomas
Arita, H., Narita, Y., Yoshida, A., Hashimoto, N., Yoshimine, T., & Ichimura, K. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0197-x · Cited by 58
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 62
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma
Morokoff, A. P., Ng, W., Gogos, A., & Kaye, A. H. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.02.008 · Cited by 55
Genotype-targeted local therapy of glioma
Shankar, G. M., Kirtane, A. R., Miller, J. J., Mazdiyasni, H., Rogner, J., Tai, T., Williams, E. A., Higuchi, F., Juratli, T. A., Tateishi, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805751115 · Cited by 54
Characterization of metabolites in infiltrating gliomas using ex vivo1H high‐resolution magic angle spinning spectroscopy
Elkhaled, A., Jalbert, L. E., Constantin, A., Yoshihara, H. A. I., Phillips, J. J., Molinaro, A. M., Chang, S. M., & Nelson, S. J. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3097 · Cited by 52
Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas
Chen, R., Ravindra, V. M., Cohen, A. L., Jensen, R. L., Salzman, K. L., Prescot, A. P., & Colman, H. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14745 · Cited by 50
In vivo detection of 2‐hydroxyglutarate in brain tumors by optimized point‐resolved spectroscopy (PRESS) at 7T
Ganji, S., An, Z., Tiwari, V., McNeil, S. S., Pinho, M. C., Pan, E., Mickey, B., Maher, E. A., & Choi, C. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26190 · Cited by 50
Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas
Jiang, S., Wen, Z., Ahn, S. S., Cai, K., Paech, D., Eberhart, C. G., & Zhou, J. (2022) · NMR in Biomedicine · doi:10.1002/nbm.4731 · Cited by 48
Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma
Xin, H., Lai, Q., Zhou, Y., He, J., Song, Y., Liao, M., Sun, J., Li, M., Zhang, M., Liang, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1134521 · Cited by 48
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas
Zhou, M., Zhou, Y., Liao, H. V., Rowland, B. C., Kong, X., Arvold, N. D., Reardon, D. A., Wen, P. Y., Lin, A., & Huang, R. Y. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy022 · Cited by 48
Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla
Verma, G., Mohan, S., Nasrallah, M. P., Brem, S. S., Lee, J. Y. K., Chawla, S., Wang, S., Nagarajan, R., Thomas, M. A., & Poptani, H. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1035-1 · Cited by 47
Self-citation
Metabolomic profiling of hormone-dependent cancers: a bird's eye view
Lloyd, S. M., Arnold, J. M., & Sreekumar, A. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.07.001 · Cited by 48
Advanced Hadamard-encoded editing of seven low-concentration brain metabolites: Principles of HERCULES
Oeltzschner, G., Saleh, M. G., Rimbault, D., Mikkelsen, M. E., Chan, K. L., Puts, N. A. J., & Edden, R. A. E. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.10.002 · Cited by 46
A computer-aided grading of glioma tumor using deep residual networks fusion
Tripathi, P. C., & Bag, S. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106597 · Cited by 47
A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1
Klink, B., Miletić, H., Stieber, D., Huszthy, P. C., Valenzuela, J. A. C., Balß, J., Wang, J., Schubert, M., Sakariassen, P. Ø., Sundstrøm, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059773 · Cited by 44
Imaging Genomics of Glioblastoma
Elbanan, M., Amer, A. M., Zinn, P. O., & Colen, R. R. (2014) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2014.09.010 · Cited by 45
Magnetic Resonance (MR) Metabolic Imaging in Glioma
Chaumeil, M. M., Lupo, J., & Ronen, S. M. (2015) · Brain Pathology · doi:10.1111/bpa.12310 · Cited by 44
Determination of N-nitrosamines and nicotine in air particulate matter samples by pressurised liquid extraction and gas chromatography-ion trap tandem mass spectrometry
Aragón, M., Marcé, R. M., & Borrull, F. (2013) · Talanta · doi:10.1016/j.talanta.2013.07.010 · Cited by 44
A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas
Impériale, A., Moussallieh, F., Sebag, F. A., Brunaud, L., Barlier, A., Elbayed, K., Bachellier, P., Goichot, B., Pacák, K., Namer, I. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080539 · Cited by 43
Analyzing Tumor Metabolism In Vivo
Faubert, B., & DeBerardinis, R. J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121954 · Cited by 44
Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma
Verma, G., Chawla, S., Mohan, S., Wang, S., Nasrallah, M. P., Sheriff, S., Desai, A. S., Brem, S. S., O’Rourke, D. M., Wolf, R. L., et al. (2018) · NMR in Biomedicine · doi:10.1002/nbm.4042 · Cited by 43
Hyperpolarized 13C Magnetic Resonance and Its Use in Metabolic Assessment of Cultured Cells and Perfused Organs
Lumata, L., Yang, C., Ragavan, M., Carpenter, N., DeBerardinis, R. J., & Merritt, M. E. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.04.006 · Cited by 42
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation
Lazović, J., Soto, H., Piccioni, D. E., Ru, J. R. L., Li, S., Mirsadraei, L., Yong, W. H., Prins, R. M., Liau, L. M., Ellingson, B. M., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos258 · Cited by 42
Self-citation
MR spectroscopy for in vivo assessment of the oncometabolite 2‐hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T
Bisdas, S., Chadzynski, G. L., Braun, C., Schittenhelm, J., Skardelly, M., Hagberg, G. E., Ethofer, T., Pohmann, R., Shajan, G., Engelmann, J., et al. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25221 · Cited by 41
Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images
Abrol, S., Kotrotsou, A., Salem, A., Zinn, P. O., & Colen, R. R. (2017) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000117 · Cited by 41
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Maggio, I., Lodi, R., & Brandes, A. A. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00537-3 · Cited by 44

Authors: Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., Wilson, N., Driggers, E., Jang, H. G., Su, S. M., Schenkein, D. P., Lai, A., Cloughesy, T. F., Kornblum, H. I., Wu, H., Fantin, V. R., & Liau, L. M.
Affiliations: University of California, Los Angeles (US)
Agios Pharmaceuticals (United States) (US)
Corresponding author: Liau, Linda M.
ORCID: Pope, Whitney B.
Prins, Robert M.
Nagarajan, Rajakumar
Yen, Katharine E.
Salamon, Noriko
Yong, William H.
Wilson, Neil
Jang, Hyun G.
Lai, Albert
Cloughesy, Timothy F.
Kornblum, Harley I.
Wu, Hong
Fantin, Valeria R.
Liau, Linda M.
Venue: Journal of Neuro-Oncology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-21
Volume: 107
Issue: 1
Pages: 197-205
ISSN: 0167-594X (ISSN-L)
1573-7373
DOI: 10.1007/s11060-011-0737-8
PMC: PMC3650613
OpenAlex: W2083820071
Cited by: 318
References: 32
Citations by year: 2026: 14 · 2025: 8 · 2024: 12 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 26 · 2019: 27 · 2018: 27 · 2017: 32 · 2016: 29 · 2015: 27 · 2014: 24 · 2013: 17 · 2012: 13
FWCI: 8.64
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Journal of Neuro-Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000124)
National Cancer Institute (R01CA121131, R01CA123396, K01CA111402, R01CA112358)
National Institute of Neurological Disorders and Stroke (R01NS052563)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords: 2-hydroxyglutarate, IDH1 mutation, glioma, oncometabolites, magnetic resonance spectroscopy, non-invasive cancer detection, choline, glutathione, Ki-67 proliferation index, tumor metabolites, biomarkers
MeSH terms: Adult, Aged, Aged, 80 and over, Brain Neoplasms, Chromatography, Liquid, DNA, Neoplasm, Female, Follow-Up Studies, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Magnetic Resonance Spectroscopy, Prognosis, Prospective Studies, Mass Spectrometry, Biomarkers, Tumor, Polymerase Chain Reaction, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks